2010
DOI: 10.2807/ese.15.09.19498-en
|View full text |Cite
|
Sign up to set email alerts
|

Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010

Abstract: Infection with the recently emerged pandemic influenza A(H1N1) virus causes mild disease in the vast majority of cases, but sporadically also very severe disease. A specific mutation in the viral haemagglutinin (D222G) was found with considerable frequency in fatal and severe cases in Norway, but was virtually absent among clinically mild cases. This difference was statistically significant and our data are consistent with a possible causal relationship between this mutation and the clinical outcome.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

17
207
4
4

Year Published

2010
2010
2014
2014

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 198 publications
(232 citation statements)
references
References 4 publications
17
207
4
4
Order By: Relevance
“…The CT-Sw/1204 virus also became virulent in BALB/c mice known to express predominantly α2,3-sialic acid in their lungs (24), and demonstrated enhanced infectivity and growth in human lung tissues, indicating potentially productive pulmonary replication. Notably, severe viral pneumonia attributed to efficient virus attachment to α2,3-sialic acid glycoconjugates deep in the lungs have been observed in H5N1 (25) and HA 225G variants of the pH1N1 (5,(26)(27)(28)(29)(30) virus infections. Moreover, it has been demonstrated that avian-type receptor-binding ability because of HA 225G increased pathogenicity of the pH1N1 2009 virus in nonhuman primates (31).…”
Section: Discussionmentioning
confidence: 99%
“…The CT-Sw/1204 virus also became virulent in BALB/c mice known to express predominantly α2,3-sialic acid in their lungs (24), and demonstrated enhanced infectivity and growth in human lung tissues, indicating potentially productive pulmonary replication. Notably, severe viral pneumonia attributed to efficient virus attachment to α2,3-sialic acid glycoconjugates deep in the lungs have been observed in H5N1 (25) and HA 225G variants of the pH1N1 (5,(26)(27)(28)(29)(30) virus infections. Moreover, it has been demonstrated that avian-type receptor-binding ability because of HA 225G increased pathogenicity of the pH1N1 2009 virus in nonhuman primates (31).…”
Section: Discussionmentioning
confidence: 99%
“…This lack of drift was reflected in the World Health Organization's (WHO) Vaccine formulation decisions which recommended an A/California/7/2009-like pandemic influenza A(H1N1) virus for both the southern hemisphere 2010 and the northern hemisphere 2010-11 influenza vaccines [2]. While some genetic variants have been reported such as the D222G (D239G numbering if starting at the first methionine) HA mutation which was linked with more severe outcomes following pandemic influenza virus infection [3] and a more commonly seen E391K change in the HA gene [4] during late 2009, no clear variant has predominated in a country or region and no vaccine update has been forthcoming. This report, however, describes the recent emergence in Singapore and subsequent spread of a genetic variant of the pandemic influenza A(H1N1) virus to Australia and New Zealand during their 2010 winter influenza season, where it now predominates and has been detected in some vaccine breakthroughs and fatal cases.…”
Section: Research Articlesmentioning
confidence: 99%
“…Instead, R591 is reported to compensate for it and is responsible for infecting humans (Medina and Garcia-Sastre, 2011;Mehle and Doudna, 2009;Yamada et al, 2010). Interestingly, patients infected with the 2009 pandemic virus with D222G mutation in hemagglutinin exhibited severe forms of the disease, such as pneumonia, suggesting that this mutation may have increased viral virulence (Kilander et al, 2010). However, subsequent studies revealed that the 2009 pandemic virus with only this mutation exhibited no significant increase in receptor binding, pathogenesis or transmissibility (Belser et al, 2011).…”
Section: Introductionmentioning
confidence: 99%